Blaize announces underwritten public offering of common stock

Blaize Holdings Inc. (NASDAQ: BZAI, NASDAQ: BZAIW) announced it intends to offer and sell shares of common stock in an underwritten public offering. The AI computing company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the offered shares at the public offering price, less underwriting discounts.

The offering remains subject to market and other conditions, with no assurance regarding completion timing or final size and terms. Blaize intends to use net proceeds for working capital and general corporate purposes.

Northland Capital Markets serves as sole bookrunning manager for the offering, while The Benchmark Company LLC acts as co-manager. The company filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission on January 27, 2026, which was declared effective February 4, 2026.

The El Dorado Hills, California-based company develops programmable AI platforms for inference workloads in real-world environments. Its Hybrid AI architecture combines the Blaize GSP processor with GPU-based infrastructure, enabling AI inference workloads across edge, cloud and data center environments.

Blaize solutions support computer vision, multimodal AI and sensor-driven applications across smart cities, industrial automation, telecommunications, retail, logistics and defense sectors. The company maintains operations across North America, Europe, the Middle East and Asia.

The offering will proceed only through a written prospectus and prospectus supplement. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on the commission's website. Final offering terms will be disclosed in a final prospectus supplement to be filed with the SEC.

You May Also Be Interested In

• Definium Therapeutics prices $700M public offering at $34 per share
• MoonLake prices $200 million public offering at $20 per share
• EU approves Merck's Keytruda plus Padcev for bladder cancer